Premium
Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: A synthesis of published evidence
Author(s) -
Tanou Kalliopi,
Zintzaras Elias,
Kaditis Athanasios G.
Publication year - 2014
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.22937
Subject(s) - medicine , allergic bronchopulmonary aspergillosis , cystic fibrosis , omalizumab , immunoglobulin e , aspergillosis , aspergillus fumigatus , immunology , dermatology , antibody
Summary Allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis (CF) is treated with corticosteroids. Since elevated IgE is a cardinal abnormality, anti‐IgE has been used sporadically as adjuvant treatment. In eight case reports, 13 children with CF and ABPA received anti‐IgE resulting in improved FEV 1 , fewer respiratory symptoms and decreased corticosteroid use. Pediatr Pulmonol. 2014; 49:503–507. © 2013 Wiley Periodicals, Inc.